Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Real Chemistry announced a pair of senior hires on Thursday, highlighted by the appointment of IPG and Omnicom alum Jeff ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions ... produce 11,000 metric tons of hydrogen per year when it starts up in 2027. Biogen will get up to $250 ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Best Of BPR 2/13: Elon Musk Gave MIT Economist Jon Gruber Whiplash & Democracy When? February 13, 2025 • Today: Jon Gruber, head of MIT's economics department, joins to discuss Elon Musk's ...

Biogen Pharmachem Industries Ltd share price was up by 3.96% from the previous closing price of ₹1.01. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...